Advil vs Abridge

Side-by-side comparison of AI visibility scores, market position, and capabilities

Abridge leads in AI visibility (41 vs 21)
Advil logo

Advil

EmergingHealthcare

General

Global #1 OTC ibuprofen brand owned by Haleon (LSE/NYSE: HLN, GSK 2022 spinoff); Pfizer exited $3B+ stake early 2025 with ADA Seal for Advil Dual Action dental pain competing with Tylenol and Aleve for OTC analgesic market.

AI VisibilityBeta
Overall Score
D21
Category Rank
#554 of 1158
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
29
Perplexity
14
Gemini
23

About

Advil is a global over-the-counter ibuprofen pain relief brand — owned by Haleon plc (LSE: HLN / NYSE: HLN), the consumer healthcare company spun off from GSK on July 18, 2022, with Pfizer completing its full stake exit in early 2025 for $3+ billion — providing consumers with 23+ ibuprofen-based product varieties for pain, headache, cold, and sleep management including Advil Extra Strength, Advil Rapid Release Gels, Advil PM, Advil Dual Action (ibuprofen + acetaminophen), and Children's Advil. Advil entered the US market in 1984 (the first OTC ibuprofen in America, considered the "most famous prescription-to-OTC switch in history") and generates approximately $800 million+ annually as one of Haleon's flagship brands alongside Sensodyne, Panadol, Centrum, and Theraflu. In September 2024, Advil Dual Action became the first OTC pain reliever to earn the American Dental Association (ADA) Seal of Acceptance for temporary management of acute dental pain.

Full profile
Abridge logo

Abridge

EmergingHealthcare

General

Pittsburgh ambient clinical AI (founded by cardiologist) at $5.3B valuation Jun 2025; $800M total ($300M a16z/Khosla Series E) deployed at UPMC 12K clinicians, Mayo Clinic, Johns Hopkins competing with Nuance DAX for physician documentation.

AI VisibilityBeta
Overall Score
C41
Category Rank
#777 of 1158
AI Consensus
50%
Trend
up
Per Platform
ChatGPT
35
Perplexity
49
Gemini
33

About

Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led by Andreessen Horowitz and Khosla Ventures at a $5.3 billion valuation, following a $250 million Series D just four months prior at a $2.8 billion valuation — providing physicians, nurses, and care teams at 150+ health systems with AI that automatically converts patient-clinician conversations into structured clinical notes, saving physicians an average of 3 hours daily and generating high-quality documentation from UPMC (scaling to 12,000 clinicians enterprise-wide), Mayo Clinic, Johns Hopkins, and Emory Healthcare. Abridge's AI is trained on a proprietary dataset of over 1.5 million medical encounters, delivering specialty-specific documentation through deep Epic EHR integration. Founded in 2018 by cardiologist Dr. Shiv Rao.

Full profile

AI Visibility Head-to-Head

21
Overall Score
41
#554
Category Rank
#777
64
AI Consensus
50
up
Trend
up
29
ChatGPT
35
14
Perplexity
49
23
Gemini
33
25
Claude
51
18
Grok
38

Key Details

Category
General
General
Tier
Emerging
Emerging
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.